Skip to main content

Advertisement

SpringerLink
Log in

Dendritic cell immunotherapy for brain tumors

  • Editors' Invited Manuscript
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Glioblastomas are characterized by immunosuppression, rapid proliferation, angiogenesis, and invasion into the surrounding brain parenchyma. Limitations in current therapeutic approaches have spurred the development of personalized, patient-specific treatments. Among these, active immunotherapy has emerged as a viable option for glioma treatment. The ability to generate an immune response utilizing patient-derived dendritic cells (DCs) (professional antigen-presenting cells) is especially attractive. This approach to glioma treatment allows for the immunologic targeting and destruction of malignant cells. Data acquired in multiple pre-clinical models and clinical trials have shown significant responses and prolonged survival. Here we provide an overview of the current status of DC vaccination for the treatment of gliomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  CAS  PubMed  Google Scholar 

  2. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674

    Article  CAS  PubMed  Google Scholar 

  3. Yamanaka R, Kajiwara K (2012) Dendritic cell vaccines. Adv Exp Med Biol 746:187–200

    Article  CAS  PubMed  Google Scholar 

  4. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM et al (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068

    Article  CAS  Google Scholar 

  5. Trumpfheller C, Longhi MP, Caskey M, Idoyaga J, Bozzacco L, Keler T et al (2012) Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med 271:183–192

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Steinman RM, Idoyaga J (2010) Features of the dendritic cell lineage. Immunol Rev 234:5–17

    Article  CAS  PubMed  Google Scholar 

  7. Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449:419–426

    Article  CAS  PubMed  Google Scholar 

  8. Shurin MR, Salter RD (2009) Dendritic cells in cancer. Springer, New York

    Google Scholar 

  9. Liu K, Nussenzweig MC (2010) Origin and development of dendritic cells. Immunol Rev 234:45–54

    Article  CAS  PubMed  Google Scholar 

  10. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ et al (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515–5525

    Article  CAS  PubMed  Google Scholar 

  11. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH et al (2011) Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17:1603–1615

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Caruso DA, Orme LM, Neale AM, Radcliff FJ, Amor GM, Maixner W et al (2004) Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro-oncology 6:236–246

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Tacken PJ, De Vries IJM, Torensma R, Figdor CG (2007) Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7:790–802

    Article  CAS  PubMed  Google Scholar 

  14. Kalinski P, Okada H (2010) Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol 22(3):173–182

  15. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE et al (2011) Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic–polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29:330–336

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L et al (2000) Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurg Focus 9:e8

    Article  CAS  PubMed  Google Scholar 

  17. Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B et al (2013) Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother 36:152–157

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK et al (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842–847

    CAS  PubMed  Google Scholar 

  19. Polyzoidis S, Ashkan K (2014) DCVax(R)-L-developed by Northwest Biotherapeutics. Hum Vaccine Immunother 10:3139–3145

    Article  Google Scholar 

  20. Jouanneau E, Black KL, Veiga L, Cordner R, Goverdhana S, Zhai Y et al (2014) Intrinsically de-sialylated CD103(+) CD8 T cells mediate beneficial anti-glioma immune responses. Cancer Immunol Immunother 63:911–924

    Article  CAS  PubMed  Google Scholar 

  21. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S et al (2008) Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68:5955–5964

    Article  CAS  PubMed  Google Scholar 

  22. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J et al (2008) Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14:3098–3104

    Article  PubMed  Google Scholar 

  23. Ardon H, De Vleeschouwer S, Van Calenbergh F, Claes L, Kramm CM, Rutkowski S et al (2010) Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer 54:519–525

    PubMed  Google Scholar 

  24. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE II, Lally-Goss D et al (2009) An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 8:2773–2779

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA et al (2012) Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 23:1043–1053

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Cao JX, Zhang XY, Liu JL, Li D, Li JL, Liu YS et al (2014) Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis. PLoS ONE 9:e107173

    Article  PubMed Central  PubMed  Google Scholar 

  27. Butowski N (2010) Immunostimulants for malignant gliomas. Neurosurg Clin N Am 21:53–65

    Article  PubMed  Google Scholar 

  28. Kamimura K, Suda T, Zhang G, Liu D (2011) Advances in gene delivery systems. Pharm Med 25:293–306

    Article  Google Scholar 

  29. Rainov NG, Heidecke V (2011) Clinical development of experimental virus-mediated gene therapy for malignant glioma. Anti-cancer Agents Med Chem (Former Curr Med Chem Anti-cancer Agents) 11:739–747

    CAS  Google Scholar 

  30. Chiocca EA, Smith KM, McKinney B, Palmer CA, Rosenfeld S, Lillehei K et al (2008) A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther 16:618–626

    Article  CAS  PubMed  Google Scholar 

  31. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I (2011) Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 17:2619–2627

    Article  CAS  PubMed  Google Scholar 

  32. Pluhar GE, Grogan PT, Seiler C, Goulart M, SantaCruz KS, Carlson C et al (2010) Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine 28:3371–3378

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Colombo F, Barzon L, Franchin E, Pacenti M, Pinna V, Danieli D et al (2005) Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther 12:835–848

    Article  CAS  PubMed  Google Scholar 

  34. Serre K, Mohr E, Gaspal F, Lane PJ, Bird R, Cunningham AF et al (2010) IL-4 directs both CD4 and CD8 T cells to produce Th2 cytokines in vitro, but only CD4 T cells produce these cytokines in response to alum-precipitated protein in vivo. Mol Immunol 47:1914–1922

    Article  CAS  PubMed  Google Scholar 

  35. Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK et al (2007) Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med 5:67

    Article  PubMed Central  PubMed  Google Scholar 

  36. Sonabend AM, Velicu S, Ulasov IV, Han Y, Tyler B, Brem H et al (2008) A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma. Anticancer Drugs 19:133–142

    Article  CAS  PubMed  Google Scholar 

  37. Mitchell DA, Batich KA, Gunn MD, Huang M-N, Sanchez-Perez L, Nair SK et al (2015) Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519:366–369

    Article  CAS  PubMed  Google Scholar 

  38. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–307

    Article  CAS  PubMed  Google Scholar 

  39. Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19:5300–5309

    Article  CAS  PubMed  Google Scholar 

  40. Fong B, Jin R, Wang X, Safaee M, Lisiero DN, Yang I et al (2012) Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS ONE 7:e32614

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Curran MA, Montalvo W, Yagita H, Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107:4275–4280

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Schartner JM, Hagar AR, Van Handel M, Zhang L, Nadkarni N, Badie B (2005) Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia 51:279–285

    Article  PubMed  Google Scholar 

  44. Grauer O, Pschl P, Lohmeier A, Adema GJ, Bogdahn U (2007) Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2. J Neurooncol 82:151–161

    Article  CAS  PubMed  Google Scholar 

  45. Ribas A (2012) Tumor immunotherapy directed at PD-1. N Engl J Med 366:2517–2519

    Article  CAS  PubMed  Google Scholar 

  46. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J et al (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86:343–349

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim C, Tobias AL et al (2014) Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors. Clin Cancer Res 20(20):5290–5301

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA, 90095, USA

    Joseph P. Antonios, Richard G. Everson & Linda M. Liau

  2. Brain Research Institute, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA, 90095, USA

    Linda M. Liau

  3. Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA, 90095, USA

    Linda M. Liau

  4. Department of Neurosurgery, David Geffen School of Medicine at UCLA, University of California Los Angeles, 300 Stein Plaza, Suite 562, Box 956901, Los Angeles, CA, 90095-6901, USA

    Linda M. Liau

Authors
  1. Joseph P. Antonios
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard G. Everson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Linda M. Liau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Linda M. Liau.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Antonios, J.P., Everson, R.G. & Liau, L.M. Dendritic cell immunotherapy for brain tumors. J Neurooncol 123, 425–432 (2015). https://doi.org/10.1007/s11060-015-1830-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-015-1830-1

Keywords

Search

Navigation